These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7339948)

  • 1. [Microcrystallinic theophylline, plasma concentration and adverse effects in patients with obstructive lung disease].
    Talseth T; Kongerud J; Boye NP; Bredesen JE
    Tidsskr Nor Laegeforen; 1981 Oct; 101(29):1648-50. PubMed ID: 7339948
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
    Harder S; Staib AH; Stauder J
    Prax Klin Pneumol; 1985 Jun; 39(6):193-6. PubMed ID: 4022931
    [No Abstract]   [Full Text] [Related]  

  • 3. Theophylline toxicity induced by tetracycline.
    McCormack JP; Reid SE; Lawson LM
    Clin Pharm; 1990 Jul; 9(7):546-9. PubMed ID: 2376112
    [No Abstract]   [Full Text] [Related]  

  • 4. [Possibilities for optimizing therapy with theophylline preparations. Clinical effectiveness and side effects of microcrystalline theophylline].
    Wiesner B; Sehrt I; Iwainsky H
    Z Erkr Atmungsorgane; 1984; 162(1):11-7. PubMed ID: 6426180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
    Ranke C; Schmidt G; Oellerich M; Sybrecht GW
    Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
    [No Abstract]   [Full Text] [Related]  

  • 6. Cimetidine-theophylline interaction: report of four patients.
    Bauman JH; Kimelblatt BJ; Caraccio TR; Silverman HM; Simon GI; Beck GJ
    Ann Allergy; 1982 Feb; 48(2):100-2. PubMed ID: 6121526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of determining theophylline concentration in serum].
    Bonelli J; Dellinger C; Kraus M; Waginger H; Zanic P
    Wien Med Wochenschr; 1986 Dec; 136(23-24):641-6. PubMed ID: 3564492
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical results obtained from a new controlled release theophylline preparation.
    Nolte D
    Br J Clin Pract Suppl; 1984; 32():14-7. PubMed ID: 6432017
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical study of theophyllinemia in patients with obstructive bronchial syndrome].
    Vasiliev CB; Burnea D; Vasiliev R; Popescu C; Anastasatu C
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1983; 32(2):169-80. PubMed ID: 6316471
    [No Abstract]   [Full Text] [Related]  

  • 10. Audit of serum theophylline concentrations in patients from general practice.
    Howard JC
    J R Coll Gen Pract; 1987 Mar; 37(296):105-6. PubMed ID: 3681843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined administration of controlled release theophylline and ranitidine: a 53-day controlled survey in patients with chronic obstructive lung disease (COLD) and peptic disease.
    Dal Negro R; Turco P; Pomari C; Trevisan F; De Conti F; Cordaro CI
    Br J Clin Pract; 1987 Nov; 41(11):1004-8. PubMed ID: 3504314
    [No Abstract]   [Full Text] [Related]  

  • 12. [The relationships between the broncholytic and diuretic effects of theophylline in patients with obstructive lung diseases combined with oxalosis].
    Pospekhova GP; Kaiukov IG; Sinitsina TM; Razorenova TS
    Ter Arkh; 1997; 69(3):47-9. PubMed ID: 9229830
    [No Abstract]   [Full Text] [Related]  

  • 13. [The comparative efficacy of the prolonged-action theophylline preparations Theopek and Euphylong in elderly patients with chronic obstructive lung diseases].
    Salikova VV; Nonikov VE; Belousov IuB
    Ter Arkh; 1993; 65(8):41-4. PubMed ID: 8211801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic effects of theophylline caused by fluvoxamine.
    van den Brekel AM; Harrington L
    CMAJ; 1994 Nov; 151(9):1289-90. PubMed ID: 7954177
    [No Abstract]   [Full Text] [Related]  

  • 15. [Theophylline therapy in obstructive respiratory diseases. 1. Bioavailability and pharmacokinetics of various theophylline preparations (author's transl)].
    Wemhöner S; Oellerich M; Sybrecht G
    Prax Klin Pneumol; 1981 Jan; 35(1):36-41. PubMed ID: 7208408
    [No Abstract]   [Full Text] [Related]  

  • 16. The tolerability of a new oral controlled release theophylline preparation in patients with obstructive airways diseases.
    Nolte D; Dusik B
    Br J Clin Pract Suppl; 1984; 32():18-21. PubMed ID: 6432018
    [No Abstract]   [Full Text] [Related]  

  • 17. [Serum theophylline levels in chronic obstructive pulmonary disease patients receiving uniphyllin].
    Chang SC; Perng RP
    Zhonghua Yi Xue Za Zhi (Taipei); 1988 Jan; 41(1):37-42. PubMed ID: 3167647
    [No Abstract]   [Full Text] [Related]  

  • 18. [Optimizing of therapy with theophylline preparations in obstructive respiratory diseases. 4. Effect of theophylline on mucociliary clearance and maximal inspiratory mouth occlusion pressure].
    Schmidt G; Ranke C; Creutzig H; Oellerich M; Sybrecht GW
    Prax Klin Pneumol; 1983 Apr; 37(4):154-60. PubMed ID: 6866926
    [No Abstract]   [Full Text] [Related]  

  • 19. [The evaluation in primary care of blood theophylline in patients with chronic obstructive pulmonary disease].
    Isanta Pomar C; Subías Lorén P; Baquer Masgrau A; Auría Romeo C; Martín Moros JM; Izquierdo Clemente C
    Rev Clin Esp; 1991 Jun; 189(1):42-3. PubMed ID: 1924930
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of obstructive respiratory disorders using a new theophylline retard preparation].
    Schroers M; Merbach W; Don M
    ZFA (Stuttgart); 1982 Jun; 58(17):974-8. PubMed ID: 7113392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.